文献速递免疫规划卫生政策与健康促进

一项随机临床试验的公共卫生评估:13价肺炎球菌结合疫苗对荷兰成人疾病结局的影响

A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands.
PubMed 文献 · Vaccine · 2018-05-31

对荷兰65岁及以上成人进行的13价肺炎球菌结合疫苗(PCV13)双盲随机安慰剂对照试验开展事后分析,采用改良意向性治疗(mITT)方法评估疫苗有效性(VE)、疫苗可预防疾病发病率(VPDI)和需接种人数(NNV)。结果显示,PCV13对疫苗型肺炎球菌社区获得性肺炎和侵袭性疾病有保护效果,高危人群的VPDI更高。

要点

  • 对疫苗型肺炎球菌社区获得性肺炎的VE为37.5%(95%CI 14.3%至54.5%),对疫苗型侵袭性肺炎球菌疾病的VE为75.8%(95%CI 47.6%至88.8%)。
  • 高危人群(自报糖尿病、慢性肺病或其他基础疾病)的VPDI约为非高危人群的2至10倍,NNV低50%至90%。
  • 临床社区获得性肺炎的VE为8.1%(95%CI -0.6%至16.1%),未达统计学显著。

核心结论

  • 在婴儿PCV7-PCV10规划持续实施的背景下,成人接种PCV13可大幅降低肺炎和侵袭性肺炎球菌疾病负担。
  • 高危成人的疫苗可预防疾病发病率更高。

研究设计与样本

  • 对一项在荷兰65岁及以上成人中开展的双盲、随机、安慰剂对照PCV13试验进行事后分析。
  • 纳入所有随机受试者,采用改良意向性治疗(mITT)方法。
  • 评估疫苗有效性(VE)、疫苗可预防疾病发病率(VPDI,定义为对照组发病率减去接种组发病率)和需接种人数(NNV,基于五年保护期)。

主要发现

  • 对临床、裁定(临床加委员会判定的影像学浸润)、肺炎球菌、疫苗型肺炎球菌社区获得性肺炎、侵袭性肺炎球菌疾病和疫苗型侵袭性肺炎球菌疾病的VE(95%CI)依次为8.1%(-0.6%至16.1%)、6.7%(-4.1%至16.3%)、22.2%(2.0%至38.3%)、37.5%(14.3%至54.5%)、49.3%(23.2%至66.5%)和75.8%(47.6%至88.8%)。
  • 上述结局每10万人年观察的VPDI依次为72、37、25、25、20和15,NNV依次为277、535、816、798、1016和1342。
  • 对临床社区获得性肺炎,PCV13每10万人年观察减少909(-115至2013)个住院日,相当于五年内每接种22人减少一个住院日。
  • 比较高危人群(自报糖尿病、慢性肺病或其他基础疾病)与非高危人群,VE相似或更低,但高危人群基线发病率更高,VPDI约为2至10倍,NNV低50%至90%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We conducted a post-hoc analysis of a double blind, randomized, placebo-controlled trial of 13-valent pneumococcal conjugate vaccine (PCV13) among adults aged 65 years or older to assess public health impact. METHODS: For all outcomes, we included all randomized subjects, using a modified intention-to-treat (mITT) approach to determine vaccine efficacy (VE), vaccine preventable disease incidence (VPDI) defined as control minus vaccinated group incidence, and numbers needed to vaccinate (NNV) (based on a five-year duration of protection). RESULTS: Results are reported for, in order, clinical, adjudicated (clinical plus radiologic infiltrate determined by committee), pneumococcal, and vaccine-type pneumococcal (VT-Sp) community-acquired pneumonia; invasive pneumococcal disease (IPD) and VT-IPD. VEs (95% CI) for all hospital episodes were 8.1% (-0.6%, 16.1%), 6.7% (-4.1%, 16.3%), 22.2% (2.0%, 38.3%), 37.5% (14.3%, 54.5%), 49.3% (23.2%, 66.5%), and 75.8% (47.6%, 88.8%). VPDIs per 100,000 person-years of observation (PYOs) were 72, 37, 25, 25, 20, and 15 with NNVs of 277, 535, 816, 798, 1016, and 1342. For clinical CAP, PCV13 was associated with a reduction of 909 (-115, 2013) hospital days per 100,000 PYOs translating to a reduction over 5 years of one hospital day for every 22 people vaccinated. When comparing at-risk persons (defined by self-report of diabetes, chronic lung disease, or other underlying conditions) to not at-risk persons, VEs were similar or lower, but because baseline incidences were higher the VPDIs were approximately 2-10 times higher and NNVs 50-90% lower. CONCLUSION: A public health analysis of pneumonia and IPD outcomes in a randomized controlled trial found substantial burden reduction following adult PCV13 immunization implemented in a setting with an ongoing infant PCV7-PCV10 program. VPDIs were higher among at-risk adults. FUNDING: The original study and the current analysis were funded by Pfizer.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gessner BD, Jiang Q, Van Werkhoven CH, et al. A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands. Vaccine. 2018. PMID: 29861177. doi:10.1016/j.vaccine.2018.05.097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。